ALVMG Stock Overview
Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally.
Visiomed Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.18|
|52 Week High||€0.46|
|52 Week Low||€0.084|
|1 Month Change||-4.60%|
|3 Month Change||-3.84%|
|1 Year Change||-52.69%|
|3 Year Change||-87.92%|
|5 Year Change||-99.74%|
|Change since IPO||-99.94%|
Recent News & Updates
|ALVMG||FR Medical Equipment||FR Market|
Return vs Industry: ALVMG underperformed the French Medical Equipment industry which returned -5.6% over the past year.
Return vs Market: ALVMG underperformed the French Market which returned -6.3% over the past year.
|ALVMG Average Weekly Movement||20.2%|
|Medical Equipment Industry Average Movement||7.0%|
|Market Average Movement||5.9%|
|10% most volatile stocks in FR Market||10.0%|
|10% least volatile stocks in FR Market||3.4%|
Stable Share Price: ALVMG is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: ALVMG's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally. It provides thermometers, blood pressure monitors, pulse oximeters, connected blood glucometers, and connected electrocardiograms; and pain relief products, such as electrotherapy. The company also offers connected scales and scalable baby scales, as well as prevention and treatment products, such as humidifiers and phototherapies.
Visiomed Group Fundamentals Summary
|ALVMG fundamental statistics|
Is ALVMG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALVMG income statement (TTM)|
|Cost of Revenue||€7.79m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.019|
|Net Profit Margin||-62.08%|
How did ALVMG perform over the long term?See historical performance and comparison
Is Visiomed Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALVMG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALVMG's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALVMG is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Medical Equipment industry average.
PE vs Market: ALVMG is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALVMG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALVMG is overvalued based on its Price-To-Book Ratio (3x) compared to the FR Medical Equipment industry average (2.2x).
How is Visiomed Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Visiomed Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Visiomed Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALVMG is currently unprofitable.
Growing Profit Margin: ALVMG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALVMG is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare ALVMG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVMG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).
Return on Equity
High ROE: ALVMG has a negative Return on Equity (-31.67%), as it is currently unprofitable.
How is Visiomed Group's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALVMG's short term assets (€16.0M) do not cover its short term liabilities (€23.5M).
Long Term Liabilities: ALVMG's short term assets (€16.0M) exceed its long term liabilities (€6.5M).
Debt to Equity History and Analysis
Debt Level: ALVMG has more cash than its total debt.
Reducing Debt: ALVMG's debt to equity ratio has reduced from 42.6% to 35.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALVMG has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ALVMG has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.9% each year.
What is Visiomed Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALVMG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALVMG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALVMG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALVMG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALVMG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Thomas Picquette is Managing Director & Director of Visiomed Group SA from April 2022. He was a Senior Associate at Naxicap Partners. He joined the firm in January 2019 as a Senior Associate.He worked...
Experienced Board: ALVMG's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 515.3%.
Visiomed Group SA's employee growth, exchange listings and data sources
- Name: Visiomed Group SA
- Ticker: ALVMG
- Exchange: ENXTPA
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €42.655m
- Shares outstanding: 233.60m
- Website: https://www.visiomed.fr
Number of Employees
- Visiomed Group SA
- 112, Avenue Kléber
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.